As of November 7, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Recursion Pharmaceuticals Inc. The largest reported stake is BlackRock, Inc.'s, at 8.5%. 10 filings are on record since December 23, 2025 (Schedule 13G/A, July 29, 2026).
Sell to companies like Recursion Pharmaceuticals Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: State Street Corporation · Sole voting: 0 · Shared voting: 33,433,905 · Sole dispositive: 0 · Shared dispositive: 34,706,130 · SCHEDULE 13G, 2026-08-07
- · Reporting person: Vanguard Portfolio Management · Sole voting: 237,675 · Shared voting: 0 · Sole dispositive: 31,369,274 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-31
- · Reporting person: Vanguard Capital Management · Sole voting: 3,978,189 · Shared voting: 0 · Sole dispositive: 26,744,129 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-31
- · Reporting person: BlackRock, Inc. · Sole voting: 43,812,201 · Shared voting: 0 · Sole dispositive: 44,541,605 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-29
- · Holder: State Street Corporation · Percent: 5.5% · SCHEDULE 13G
Recursion Pharmaceuticals Inc has 10 Schedule 13D or 13G filings on record since 2025-12-23. 5 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| BlackRock, Inc. | 8.5% | 44,541,605 | SCHEDULE 13G/A, 2026-07-29 | 2026-06-30 |
| ARK Investment Management LLC | 7.25% | 37,316,856 | SCHEDULE 13G/A, 2026-02-03 | 2025-12-31 |
| State Street Corporation | 6.6% | 34,706,130 | SCHEDULE 13G, 2026-08-07 | 2026-06-30 |
| Vanguard Portfolio Management | 5.97% | 31,369,274 | SCHEDULE 13G, 2026-07-31 | 2026-06-30 |
| Vanguard Capital Management | 5.09% | 26,744,129 | SCHEDULE 13G, 2026-07-31 | 2026-06-30 |
| Baillie Gifford & Co | 4.6% | 23,774,972 | SCHEDULE 13G/A, 2026-02-05 | 2025-12-31 |
| Mubadala Investment Co PJSC | 1.4% | 0 | SCHEDULE 13D/A, 2025-12-23 | 2024-11-20 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
Holding shares or following this stake? See who's behind Recursion Pharmaceuticals Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Recursion Pharmaceuticals Inc and the records around it.
Recursion Pharmaceuticals Inc elsewhere on the record
- Leadership changes Apr 2026
- Who owns it
Companies that share a holder
- Mubadala Investment Co PJSC also filed stake reports on 5 other companies: Evotec SE (Oct 2026), GLOBALFOUNDRIES Inc. (Aug 2026), Blue Owl Technology Finance Corp. (Feb 2026)
- ARK Investment Management LLC also filed stake reports on 20 other companies: Tempus AI, Inc. (Nov 2026), 10x Genomics, Inc. (Oct 2026), Twist Bioscience Corp (Sep 2026)
- BAILLIE GIFFORD & CO also filed stake reports on 39 other companies: QXO, Inc. (Oct 2026), Reddit, Inc. (Oct 2026), Samsara Inc. (Oct 2026)
Watch Recursion Pharmaceuticals Inc
Get an email when Recursion Pharmaceuticals Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Recursion Pharmaceuticals Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Recursion Pharmaceuticals Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Recursion Pharmaceuticals Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | 43,812,201 | 0 | 44,541,605 | 0 | SCHEDULE 13G/A, 2026-07-29 |
| State Street Corporation | 0 | 33,433,905 | 0 | 34,706,130 | SCHEDULE 13G, 2026-08-07 |
| Vanguard Portfolio Management | 237,675 | 0 | 31,369,274 | 0 | SCHEDULE 13G, 2026-07-31 |
| Vanguard Capital Management | 3,978,189 | 0 | 26,744,129 | 0 | SCHEDULE 13G, 2026-07-31 |
The latest filing identifies Recursion Pharmaceuticals Inc by CUSIP 75629V104 and gives its principal executive office as 41 SOUTH RIO GRANDE STREET, SALT LAKE CITY, UT 84101 (SCHEDULE 13G, 2026-08-07).
Purpose of Transaction (Item 4)
Mubadala Investment Co PJSC
On March 31, 2023, MIC LP transferred the 1,388,889 Common Shares that it then held to MCAS. As a result, as of such time, MCAS directly held 1,388,889 Common Shares and MIC LP ceased to beneficially own any Common Shares. In addition, the Issuer and Exscientia plc, a public limited company incorporated under the laws of England and Wales ("Exscientia"), entered into a transaction agreement, dated as of August 8, 2024, as amended (the "Transaction Agreement"). The Transaction Agreement provided that, subject to the conditions set forth therein, the Issuer would acquire the entire issued and to be issued share capital of Exscientia pursuant to a scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme of Arrangement" and such transaction, the "Transaction"). The Transaction closed on November 20, 2024. Under the Transaction Agreement, pursuant to and following the effective time of the Scheme of Arrangement (the "Effective Time"), each ordinary share in Exscientia (each an "Exscientia Share") was automatically acquired by the Issuer in exchange for 0.7729 Common Shares. Accordingly, at the Effective Time, MIC Europe received, in exchange for the 1,542,600 Exscientia Shares that it then held, 1,192,275 Common Shares. As a result, at the Effective Time, MIC Europe directly held 1,192,275 Common Shares and MIC UK beneficially owned 2,581,164 Common Shares. In addition, between December 18, 2025, and the date hereof, Fifteenth sold a total of …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-12-23; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-12-23 | Mubadala Investment Co PJSC | 1.4% | SCHEDULE 13D/A |
| 2026-02-03 | ARK Investment Management LLC | 7.25% | SCHEDULE 13G/A |
| 2026-02-05 | Baillie Gifford & Co | 4.6% | SCHEDULE 13G/A |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-24 | BlackRock, Inc. | 7.2% | SCHEDULE 13G/A |
| 2026-05-12 | State Street Corporation | 5.5% | SCHEDULE 13G |
| 2026-07-29 | BlackRock, Inc. | 8.5% | SCHEDULE 13G/A |
| 2026-07-31 | Vanguard Capital Management | 5.09% | SCHEDULE 13G |
| 2026-07-31 | Vanguard Portfolio Management | 5.97% | SCHEDULE 13G |
| 2026-08-07 | State Street Corporation | 6.6% | SCHEDULE 13G |
Questions about who owns Recursion Pharmaceuticals Inc
Who owns Recursion Pharmaceuticals Inc?
On this page, 5 holders' latest ownership filings report 5% or more of Recursion Pharmaceuticals Inc: BlackRock, Inc. (8.5%, Schedule 13G/A, filed 2026-07-29), ARK Investment Management LLC (7.25%, Schedule 13G/A, filed 2026-02-03), State Street Corporation (6.6%, Schedule 13G, filed 2026-08-07), Vanguard Portfolio Management (5.97%, Schedule 13G, filed 2026-07-31) and Vanguard Capital Management (5.09%, Schedule 13G, filed 2026-07-31).
Who are the largest shareholders of Recursion Pharmaceuticals Inc?
By the share each holder's latest filing reports, the largest holders of Recursion Pharmaceuticals Inc on this page are BlackRock, Inc. (8.5%), ARK Investment Management LLC (7.25%) and State Street Corporation (6.6%).
When did BlackRock, Inc. buy into Recursion Pharmaceuticals Inc?
The filings give report dates, not purchase dates. The earliest filing from BlackRock, Inc. on this page is the Schedule 13G/A, filed 2026-04-24, reporting 7.2%; its latest, Schedule 13G/A filed 2026-07-29, reports 8.5%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Recursion Pharmaceuticals Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 2, 2026 | Leadership change: Fred Hassan appointed, Chair of the Board, and 1 more | — | Leadership changes | Source |
| April 30, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Recursion Pharmaceuticals Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.